Pharmacokinetic properties of itraconazole in blue-fronted amazon parrots (Amazona aestiva aestiva)

Journal of Avian Medicine and Surgery

Volumn 10, Issue 3, 1996, Pages 168-173

  Orosz, Susan E ^a   Frazier, Donita L ^a   Schroeder, Edward C ^a   Cox, Sherry K ^a   Schaeffer, Dorcas O ^a   Doss, Sonia ^a   Morris, Patrick J ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b INSTITUTE FOR CONSERVATION RESEARCH   (United States)

Author keywords

Aspergillosis; Aspergillus; Birds; Itraconazole; Parrots

Indexed keywords

EID: 0010660803     PISSN: 10826742     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. van den Bossche H, Willemsems G, Cools W, et al. Hypothesis on the molecular basis of the antifungal activation of N-substituted imidazoles and triazoles. Biochem Soc Trans 1983;11:665-667.
2. Harvey SC. Antiseptics, disinfectants, fungicides, ectoparasitacides. In: Gilman AF, Goodman LS, Rall TW, Murad F (eds) Goodman and Gilmans's the pharmacological basis of therapeutics. 7th ed. New York, Macmillan, 1985:973-976.
3. DeNollin S, Van Belle H, Goossens F, et al. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother 1977;11:500-513.
4. Uno J, Shigematsu ML, Arai T. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother 1982;21:912-918.
5. Graybill JR. New antifungal agents. Eur J Clin Microbiol Infect Dis 1989;8:402-412.
6. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-344.
7. Heykants J, Michiels M, Meudermans W, et al. The pharmacokinetics of itraconazole in animals and man: an overview. In: Fromtling RA (ed). Recent trends in the discovery, developments and evaluation of antifungal agents. Barcelona: JR Prous, 1987:223-249.
8. Cauwenbergh G, DeDoncker P, Stoops K, et al. Itraconazole in the treatment of human mycoses. Review of 3 years of clinical experience. Rev Infect Dis 1987;9(Suppl 1):S146-S152.
9. Boelaert J, Schugers MG, Dunn JF, et al. High-dose itraconazole in the treatment of human mycoses. Review of 3 years of clinical experience. Rev Infect Dis 1987.
10. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral system availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-426.
11. Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infections. J Am Acad Dermatol 1987;17: 220-223.
12. Barone JA, Koh JH, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-784.
13. Stein A, Daneshmend TK, Warnock DW, et al. The effects of H2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br J Clin Pharmacol 1989;27:105-106.
14. Lim SG, Sawyer AM, Hudson M, et al. Short report: the absorption of fluconazole and itraconazole under conditions of low gastric acidity. In: Fromtling RA (ed). Recent trends with the discovery, developments and evaluation of antifungal agents. Barcelona: JR Prous, 1987:223-249.
15. Hines RS, Sharkey P, Friday RB. Itraconazole treatment of pulmonary, ocular, and uropygeal aspergillosis and candidiasis in birds - data from five clinical cases and controls. Proc Am Assoc Zoo Vet 1990: 322-327.
16. Forbes NA. Diagnosis of avian aspergillosis and treatment with itraconazole. Vet Rec 1991;128:263.
17. Joseph V, Pappagianis D, Reavill DR. Clotrimazole nebulization for the treatment of respiratory aspergillosis. Proc Annu Conf Assoc Avian Vet 1994:301-306.
18. Orosz SE, Frazier DL. Antifungal agents: a review of their pharmacology and therapeutic indications. J Avian Med Surg 1995;9:8-18.
19. Lumeij JT, Gorgevska D, Worstenborghs R. Plasma and tissue concentrations of itraconazole in racing pigeons. J Avian Med Surg 1995;9:32-35.
20. Orosz SE, Schroeder EC, Cox SK, et al. The effects of formulation on the systemic availability of itraconazole in pigeons. J Avian Med Surg 1995;9:255-262.
21. Ritchie BW, Harrison GJ, Harrison LR (eds). Appendix. Avian medicine: principles and application. Lake Worth, FL: Wingers, 1994:1329-1351.
22. Herpol C. Influence de l'ago sur le pH dons le tube digestif de gallus domesticus. Ann Biol Anim Biochim Biophys 1966;6:495.
23. Herpol C, van Grembergen G. La signification du pH dons le tube digestif de gallus domesticus. Ann Biol Anim Biochim Biophys 1967;7:33.
24. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-1313.
25. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses; animal models. Rev Infect Dis 1987;9:15-32.
26. Van Cutsem J, Janssen PAJ. In vitro and in vivo models to study the activity of antifungals against aspergillus. In: Van den Bossche H, MacKenzie DWK, Cauwenberg G (eds). Aspergillus and aspergillosis. New York: Plenum, 1987;215-227.
27. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycosis 1989;32:103-108.
28. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical interactions. Clin Infect Dis 1992;14:165-174.
29. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole, and amphotericin B. Chemotherapy 1994;40:92-98.